Disease recurrence after radical prostatectomy: Contemporary diagnostic and therapeutical strategies

Minerva Urologica e Nefrologica

Volumn 55, Issue 4, 2003, Pages 251-261

  Augustin, H ^a   Hammerer, P G ^b,c  

^a UNIVERSITY OF GRAZ   (Austria)

^b Hospital Braunschweig   (Germany)

^c KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

Prostate specific antigen; Prostatectomy; Prostatic neoplasms, therapy; Recurrence

Indexed keywords

ANDROGEN; ANDROSTANOLONE; BICALUTAMIDE; CAPROMAB PENDETIDE IN 111; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

BONE SCINTISCANNING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIGITAL RECTAL EXAMINATION; GYNECOMASTIA; HUMAN; MALE; MASTALGIA; MEDLINE; METASTASIS; MONOTHERAPY; ORCHIECTOMY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT INDICATION;

DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 1542378350     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer Statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Carter BH, Sauvageot J, Walsh PC, Epstein JJ. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol 1997;157:2206-7.
3. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. Eur Urol 2000;38:74-8.
4. Guillonneau B, Rozet F, Cathelineau X, Lay F, Barret E, Doublet JD et al. Perioperative complications of laparoscopic radical prostatectomy: the Montsouris 3-year experience. J Urol 2002;167:51-6.
5. Augustin H, Hammerer P, Graefen M, Palisaar J, Noldus J, Fernandez S et al. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol 2003;43:113-8.
6. Ruiz-Deya G, Davis R, Srivastav SK, M Wise A, Thomas R. Outpatient radical prostatectomy: impact of standard perineal approach on patient outcome. J Urol 2001;166:581-6.
7. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34.
8. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-65.
9. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164:101-5.
10. Inselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol 1999;161:163-8.
11. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
12. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after radical prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
13. Zincke H, Oesterling JE, Bluthe ML, Bergstralh EJ, Myers RP, Barrett DM. Long term (15-years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-7.
14. Trapasso JG, deKernion JB, Smith RP, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821-5.
15. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994;152:1843-9.
16. Leibman BD, Dillioglugil O, Wheeler TM, Scardino PT. Distant metastasis after radical prostatectomy in patients without an elevated serum prostatic antigen level. Cancer 1995;76:2530-4.
17. Oefelein MG, Smith N, Carter M, Dalton D, Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol 1995;154:2128-31.
18. Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 2001;19:3692-705.
19. Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol 1999;36:21-30.
20. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive margins in radical prostatectomy specimens. J Urol 1995;154:1818-24.
21. Grossfeld GD, Chang JJ, Broering JM, Miller DP, Yu J, Flanders SC et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPUSRE database. J Urol 2000;163:1171-7.
22. Watson RB, Civantos F, Soloway MS. Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology 1996;48:80-90.
23. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:139-58.
24. Stapleton AM, Zbell P, Kattan MW, Yang G, Wheeler TM, Scardino PT et al. Assessment of the biological markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 1998;82:168-75.
25. Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120:159-66.
26. Ross PL, Scardino PT, Kattan MW. A catalogue of prostate cancer nomograms. J Urol 2001;165:1562-8.
27. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507.
28. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Tomaszewski JE et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 1998;160:2096-101.
29. Kattan MW, Eastham JA, Stapelton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
30. Porter CP, O'Donnell C, Crawford ED, Gamito EJ, Errejon A, Genega E et al. Artificial neural network model to predict biochemical failure following radical prostatectomy. Mol Urol 2001;5:159-62.
31. Villers A. PSA in a follow-up after radical prostatectomy: a review. In: Murphy G, Griffiths K, Denis L, Khoury S, Chatelain C, editors. Proceedings from the First International Consultation on Prostate Cancer. Scientific Communication International Ltd Publishers; 1997.
32. Schild SE, Wong WW, Novicki DE, Ferrigni RG, Swanson SK. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Urology 1996;47:878-81.
33. Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Ultrasensitive detection of prostate specific antigen in the follow-up of 422 patients after radical prostatectomy. J Urol 1999;161:1206-11.
34. Yu H, Eleftherios DP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 μGL. J Urol 1997;157:913-8.
35. Lange PH, Ligthner DJ, Medini E, Reddy PK, Vessella RL. The effect of radiation therapy after radical prostatectomy in patients with elevated PSA levels. J Urol 1990;144:927-32.
36. Stein A, deKernion JB, Smith RB, Dorey F, Patel H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992;147:942-6.
37. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-59.
38. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence pattern after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slop prostate specific antigen. J Urol 1997;158:1441-5.
39. Connolly JA, Shinohara K, Presti JC jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate specific antigen and positive surgical margin. Urology 1996;47:225-31.
40. Pound CR, Christens-Barry OW, Gurganus RT, Partin AW, Walsh PC. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 1999;162:1337-40.
41. Whitmore WF jr. Natural history and staging of prostate cancer. Urol Clin North Am 1984;11:209-20.
42. Oesterling JE. Prostate-specific antigen: a critical assessment of the most useful marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
43. Cher ML, Bianco FJ jr, Lam JS, Davis LP, Grignon DJ, Sakr WA et al. Limited role of radionuclide bone scintigraphy in patients with PSA elevation after radical prostatectomy. J Urol 1998;160:1387-91.
44. Wassermann NF, Kapoor DA, Hildebrandt WC, Zhang G, Born KM, Eppel SM et al. Transrectal US in evaluation of patients after radical prostatectomy. Part I. Normal postoperative anatomy. Radiology 1992;185:361-6.
45. Wassermann NF, Kapoor DA, Hildebrandt WC, Zhang G, Born KM, Eppel SM et al. Transrectal US in evaluation of patients after radical prostatectomy. Part II. Transrectal US and biopsy findings in the presence of residual and early recurrent prostatic cancer. Radiology 1992;185:367-72.
46. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 2001;219:432-9.
47. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-25.
48. Lange PH, Lightner DJ, Medini E, Reddy PK, Vessella RL. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol 1990;144:927-32.
49. Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 2001;166:111-5.
50. Schild SE, Buskirk SJ, Wong WW, Halyard MY, Swanson SK, Novicki DE et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996;156:1725-9.
51. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate rebiopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17:1155-63.
52. Shekarriz B, Upadhyay J, Wood DP jr, Hinman J, Raasch J, Cummings GD et al. Vesico-urethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology 1999;54:1044-8.
53. Saleem MD, Sanders H, Abu El Naser M, El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology 1998;51:283-6.
54. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999;162:1322-8.
55. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998;83:739-47.
56. 111Labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998;51:978-84.
57. Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JM, Thames HD et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003;21:1715-21.
58. Anderson JB. Early venus deferred hormone therapy. Eur Urol 1999;36 Suppl 2:9-13.
59. Wu JJ, King SC, Montana GS, McKinstry CA, Anscher MS. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995;32:317-23.
60. Morris MM, Dallow KC, Zietman AL, Park J, Althausen A, Heney NM et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:731-6.
61. Garg MK, Tekyi-Mensah S, Bolton S, Velasco J, Pontes E, Wood DP jr et al. Impact of post prostatectomy prostate-specific antigen nadir on out-comes following salvage radiotherapy. Urology 1998;51:998-1002.
62. Forman JD, Meetze K, Pontes E, Wood DP jr, Shamsa F, Rana T et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 1997;158:1436-9.
63. Vicini FA, Ziaja EL, Kestin LL, Brabbins DS, Sromberg JS, Gonzalez JA et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999;54:111-7.
64. Catton C, Gospodarowicz M, Warde P, Panzarella T, Catton P, McLean M et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 2001;59:51-60.
65. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000;163:845-50.
66. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998;159:173-8.
67. Nudell DM, Grossfeld GD, Weinberg VK, Roach M 3rd, Carroll PR. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999;54:1049-57.
68. Huggins C, Hodges CV. Studies of prostatic cancer: I. Effect of castration, estrogen and androgen injections on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
69. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-9.
70. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
71. Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998;33:144-51.
72. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
73. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997;49:71-8.
74. Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate: treatment comparisons. J Urol 1967;98:516-9.
75. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79:235-46.
76. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
77. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001;58 (2 Suppl 1):101-7.
78. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993;71:2782-90.
79. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45:839-44.
80. De La Taille A, Zerbib M, Conquy S, Amsellem-Ouazana D, Thiounn N, Flam TA et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int 2003;91:18-22.
81. Kurek R, Renneberg H, Lubben G, Kienle E, Tunn UW. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 1999;35 Suppl 1:27-31.
82. Sciarra A, Di Chiro C, Di Silverio F. Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer. World J Urol 2000;18:392-400.
83. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000;164:1579-82.
84. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T et al. A randomised comparison of "Casodex" (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-56.
85. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003;91:455-61.